Search
-
GLP–1s: A Healthcare Revolution?
One of this century’s biggest game-changers will likely be a novel drug class that’s showing unprecedented success, or the promise of it, in treating some of the world’s most prevalent conditions.
-
Misfits and the Machine: Why AI alone can’t crack creative effectiveness
In the second of our AI in Advertising papers, we explore the benefits and limitations of using AI in ad development.
-
Conversations with AI Part VI: AI-powered moderator bots: Enhancing empathy or eroding connection?
In the sixth white paper in our Ipsos Views Conversations with AI series, we explore the role of a Moderator Bot powered by generative AI within qualitative research.
-
Ipsos Update - October 2024
Trends, News, Ageing … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
-
Predicting Opportunity in Emerging Therapies
The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.
-
Empathy or Emptiness: Unravelling the Impact of AI on Human Connection
Revisit our webinar to hear insights from pioneering studies on the interplay between AI and human moderators and respondents.
-
Conversations with AI Part V: Is there depth and empathy with AI twins?
How do synthetic respondents fall short of capturing the human experience?
-
Unveiling the Swiss telecom landscape through consumers' eyes
Exploring Swiss Telecom Brands: Ipsos in Switzerland has delved into the telecommunications market to uncover the intricate dynamics and opportunities within the sector.